Navigation Links
Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients

that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that Soliris will not generate interest among physicians, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2007 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

1 Hillmen P. The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Study accepted for presentation at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA), on Saturday, June 9 in Vienna, Austria.

2 Schrezenmeier H. Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): SHEPHERD Phase III Clinical Study Results. Study accepted for presentation at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA), on Saturday, June 9 in Vienna, Austria.

3 Muus P. The Clinical Benefit of Eculizumab is Demonstrable in All Subpopulations of Patients with Paroxysmal Nocturnal Hemoglobinuira PNH with Hemolysis. Study accepted for oral presentation at the 12th Congress of European Hematology, organized by The European Hem
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today announced ... (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine ... disturbed behaviors in patients with schizophrenia or bipolar I ... injectable drug, InnoPharma has entered into an agreement with ... will make, use, sell, market and distribute Olanzapine ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... New data being presented at the American College ... San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) ... in a statistically significant greater percentage of nights ... disease (GERD), compared to placebo (p<0.001). In addition, ...
... SAN DIEGO, Oct. 26 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis and treatment of coronary and peripheral ... results for the third quarter and first nine months of ... hold a conference call to discuss its financial results and ...
Cached Medicine Technology:New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 2New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 3Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:7/30/2014)... as evolutionary changes in a living organismhad been thought ... genome. , However, recent studies have shown that cancer ... arise simultaneously and in close proximity to each other. ... regions where chromosomal rearrangements take place. , The discovery, ... one day lead to new cancer therapies, according to ...
(Date:7/30/2014)... News) -- Some obese people have a genetic mutation ... their brains when they see food, researchers report. ... feelings of pleasure and gratification at the sight of ... to prevent overeating, the scientists suggested. More than ... typically caused by a combination of overeating, a lack ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
(Date:7/30/2014)... 30, 2014 The American Telemedicine ... Sens. Thad Cochran (R-MS) and Roger Wicker (R-MS) ... telemedicine coverage under Medicare, Medicaid and Federal Communications ... Mississippi Republicans, introduced the Telehealth Enhancement Act as ... version, H.R. 3306, introduced by Rep. Gregg Harper ...
(Date:7/30/2014)... 2014 2014 Deep Research ... is a professional and in-depth research report ... provides basic Chitosan information, including Chitosan definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4
... 14 ECRI Institute Patient Safety Organization (PSO) ... Coalition for Quality & Patient Safety (CQPS) of ... reporting, and analysis. The Chicagoland PSO focuses on ... specific to Chicago and the surrounding counties. CQPS ...
... 14 May 2009 Research4Life today announces that ... (OARE) program has registered 1500 institutions since its ... percent. This means that scientists, researchers and environmental ... poorest countries can gain free or low cost ...
... Anpath Group, Inc. (OTC Bulleting Board: ANPG), ... (ESI) and its distributor partner, Minntech Japan Corporation, ... 36th annual meeting of the Japanese Society of ... meeting was attended by over 4,000 medical professionals. ...
... Research Month activities include spring dedication at the ... Today Intergraph(R) and the Huntsville Botanical Garden once ... at the Intergraph Garden of Hope spring dedication. ... from the Huntsville community convened to celebrate life ...
... Stem for Life FoundationNEW YORK, May 14 NeoStem, Inc. ... pre-disease collection, processing and long-term storage of adult stem cells ... agreement for Ceres Living, Inc., a developer and direct marketer ... of an innovative nutritional supplement - AIO Premium Cellular Health. ...
... GABLES, Fla., May 14 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... first quarter ended March 31, 2009. First Quarter ... the Company reported a net loss of $3,031,201, or $0.22 ... of $1,584,047, or $0.13 per basic and diluted share, for ...
Cached Medicine News:Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 2Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 3Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 4Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 5Health News:Access to environmental research in developing nations grown to 1,500 institutions 2Health News:Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 3Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 4Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 5Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 6Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 7Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 2Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 5
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
Spare fuse set...
Clock oil, 6 grams net...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: